Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 21,050	$ 19,055
Prepaid expenses and other current assets	1,263	2,515
Total Current Assets	22,313	21,570
Property and equipment, net	943	905
Deposits and other assets	23	23
Total Assets	23,279	22,498
Current Liabilities:
Accounts payable	1,097	1,993
Accrued expenses	2,070	2,627
Warrant liabilities	12,664	14,821
Accrued employee benefits	1,606	313
Deferred rent	88	3
Total Current Liabilities	17,525	19,757
Long term deferred rent	426	492
Total Liabilities	17,951	20,249
Stockholders' Equity:
Common stock, $0.001 par value; 350,000,000 shares authorized; 128,648,365 and 117,254,196 shares issued; and 128,566,883 and 117,172,714 shares outstanding	129	117
Additional paid-in capital	192,042	175,762
Accumulated deficit	(196,959)	(172,034)
Total Synthetic Biologics, Inc. and Subsidiaries (Deficit) Equity	(4,788)	3,845
Non-controlling interest	(1,876)	(1,596)
Total Stockholders' (Deficit) Equity	(6,664)	2,249
Total Liabilities and Stockholders' (Deficit) Equity	23,279	22,498
Series A Preferred Stock [Member]
Current Liabilities:
Series A convertible preferred stock, $0.001 par value; 10,000,000 and zero shares authorized; 120,000 and zero shares issued and outstanding	$ 11,992	$ 0